INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
Boca Raton, Florida — INmune Bio Inc. (NASDAQ: INMB), a biotechnology company currently in the clinical stage, is committed to leveraging the innate immune system to combat diseases. The firm has announced its participation in several key investor conferences scheduled for September and October.
Details on the Baird Conference
The Baird 2024 Global Healthcare Conference will take place on September 10-11, 2024. During this event, the management team from INmune Bio will present on Tuesday, September 10, from 8:30 to 9:00 AM Eastern Time. Their presentation is set for Session III in Empire Ballroom B, located on the Mezzanine Level.
About INmune Bio Inc.
INmune Bio, Inc. is focused on developing innovative therapeutics that strategically activate the innate immune system to fight diseases. The company boasts a strong pipeline, featuring two major product platforms currently undergoing clinical trials. One of these is the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform, which utilizes cutting-edge technology to neutralize soluble TNF, a key contributor to immune system dysfunction. XPRO, the first product from this platform, is in trials to evaluate its effectiveness in treating Mild Alzheimer’s disease. Additionally, the company plans to explore future therapeutic applications for resistant depression and oncology.
Natural Killer Cell Priming Platform
In tandem with the DN-TNF platform, INmune Bio is progressing its Natural Killer Cell Priming Platform, which includes the therapy INKmune™. This treatment is designed to activate a patient’s natural killer (NK) cells, enabling them to effectively target cancer cells. Currently, INKmune™ is being tested in a Phase I/II clinical trial for men diagnosed with metastatic castrate-resistant prostate cancer.
Contact Information
For further details, INmune Bio encourages interested parties to reach out. David Moss, the CFO, is available at (858) 964-3720 or via email at info@inmunebio.com. For investor-related inquiries, Mike Moyer, Managing Director at LifeSci Advisors, can be contacted at mmoyer@lifesciadvisors.com.
Frequently Asked Questions
What is the primary focus of INmune Bio Inc.?
INmune Bio Inc. specializes in creating treatments that harness the innate immune system to address a variety of diseases, including cancer and neurodegenerative disorders.
When will INmune Bio present at the Baird 2024 Global Healthcare Conference?
INmune Bio's presentation is set for September 10, 2024, from 8:30 to 9:00 AM Eastern Time.
What products are currently in clinical trials under INmune Bio?
INmune Bio is conducting clinical trials for two main platforms: the DN-TNF product platform featuring XPRO for Mild Alzheimer’s disease and the Natural Killer Cell Priming Platform with INKmune™ for cancer treatment.
How does INmune Bio's XPRO work?
XPRO employs dominant-negative technology to selectively neutralize soluble TNF, aiming to enhance treatment outcomes for patients suffering from Mild Alzheimer’s disease.
Where can I find more information about INmune Bio's products?
For more details on INmune Bio and its innovations, you can visit their official website at www.inmunebio.com.